Family history of Type 1 diabetes affects insulin secretion in patients with ‘Type 2’ diabetes

Authors

  • V. M. Lundgren,

    Corresponding author
    1. Folkhalsan Research Centre, Helsinki
    • Department of Medicine, Helsinki University Central Hospital, Research Program of Molecular Medicine, University of Helsinki
    Search for more papers by this author
  • M. K. Andersen,

    1. Department of Medicine, Helsinki University Central Hospital, Research Program of Molecular Medicine, University of Helsinki
    2. Folkhalsan Research Centre, Helsinki
    Search for more papers by this author
  • B. Isomaa,

    1. Folkhalsan Research Centre, Helsinki
    2. Department of Social Services and Health Care, Jakobstad, Finland
    Search for more papers by this author
  • T. Tuomi

    1. Department of Medicine, Helsinki University Central Hospital, Research Program of Molecular Medicine, University of Helsinki
    2. Folkhalsan Research Centre, Helsinki
    Search for more papers by this author

Correspondence to: Virve Lundgren. E-mail: virve.lundgren@hus.fi

Abstract

Aims

The aim was to evaluate the impact of family history of diabetes on the phenotype of patients diagnosed with Type 2 diabetes and the frequency of susceptibility genotypes.

Methods

Patients with Type 2 diabetes with family history for both Type 1 and Type 2 diabetes (FHMIX, n = 196) or Type 2 diabetes only (FHT2, n = 139) matched for age, sex, BMI and age at diagnosis, underwent an oral glucose tolerance test and a combined glucagon test and insulin tolerance test. Glutamic acid decarboxylase (GAD) antibodies and major Type 1 and Type 2 diabetes susceptibility gene variants were analysed. Patients were stratified into groups according to family history or GAD antibody positivity (GADA+, GADA–) or a combination of these (GADA+/FHMIX, GADA+/FHT2, GADA–/FHMIX, GADA–/FHT2).

Results

Compared with other patients, those with FHMIX more often had GAD antibodies (14.3 vs. 4.3%, P = 0.003), and those with both FHMIX and GAD antibodies had the highest frequency of insulin deficiency (stimulated serum C-peptide < 0.7 nmol/l, GADA+/FHMIX 46.4% vs. GADA–/FHMIX 9.5% (P < 0.00001), GADA–/FHT2 4.5% (P < 0.00001), GADA+/FHT2 0%). Patients with GADA+/FHMIX more often had HLA-DQB1 risk genotypes compared with patients with GADA–/FHMIX or GADA–/FHT2D (47 vs. 23 or 14%, P = 0.05 and P < 0.00001, respectively). In logistic regression analyses, FHMIX, GAD antibody positivity and HLA risk genotypes were independently associated with insulin deficiency.

Conclusion

A family history for both type 1 and type 2 diabetes was associated with higher prevalence of GAD antibodies and HLA-DQB1 risk genotypes than a family history of type 2 diabetes only, and was associated with earlier and more severe development of insulin deficiency, which was only partially explained by GAD antibodies and HLA.

Ancillary